These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32633149)

  • 21. Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series.
    Dell'Osso B; Cremaschi L; Palazzo MC; Spagnolin G; Cattaneo A; Grancini B; Maggi M; Altamura AC
    Expert Opin Drug Saf; 2014 Sep; 13(9):1199-208. PubMed ID: 25084462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Administration of Antipsychotic Asenapine Pre or Postnatal does not Induce Anxiety-like Behaviors in Mice.
    de Souza TB; Farias DM; Coletti RF; Oliveira MS; Carrilho CG; de Barros JA; Moreno SE; Murillo-Rodriguez E; Machado S; Veras AB
    CNS Neurol Disord Drug Targets; 2018 Mar; 16(10):1127-1133. PubMed ID: 29237385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances and challenges in nintedanib drug delivery.
    Velagacherla V; Suresh A; Mehta CH; Nayak UY
    Expert Opin Drug Deliv; 2021 Nov; 18(11):1687-1706. PubMed ID: 34556001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current advances in development of new docetaxel formulations.
    Zhang E; Xing R; Liu S; Li P
    Expert Opin Drug Deliv; 2019 Mar; 16(3):301-312. PubMed ID: 30773947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects.
    Cherniakov I; Domb AJ; Hoffman A
    Expert Opin Drug Deliv; 2015 Jul; 12(7):1121-33. PubMed ID: 25556987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asenapine maleate-loaded nanostructured lipid carriers: optimization and in vitro, ex vivo and in vivo evaluations.
    Managuli RS; Wang JT; Faruqu FN; Kushwah V; Raut SY; Shreya AB; Al-Jamal KT; Jain S; Mutalik S
    Nanomedicine (Lond); 2019 Apr; 14(7):889-910. PubMed ID: 30874464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder.
    McIntyre RS
    Expert Rev Neurother; 2010 May; 10(5):645-9. PubMed ID: 20420486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asenapine: a clinical overview.
    Potkin SG
    J Clin Psychiatry; 2011; 72 Suppl 1():14-8. PubMed ID: 22217438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia.
    Foute Nelong T; Manduca JD; Zonneveld PM; Perreault ML
    Neurosci Lett; 2019 Oct; 711():134404. PubMed ID: 31356843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid-Based Oral Formulation Strategies for Lipophilic Drugs.
    Patel V; Lalani R; Bardoliwala D; Ghosh S; Misra A
    AAPS PharmSciTech; 2018 Nov; 19(8):3609-3630. PubMed ID: 30255474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asenapine at low doses as a treatment for psychotic anxiety.
    Robles Martínez M; Fernández Monge M; Lloreda Morillo MJ
    Acta Neuropsychiatr; 2016 Aug; 28(4):246-7. PubMed ID: 26782831
    [No Abstract]   [Full Text] [Related]  

  • 32. Asenapine: Pharmacological Aspects and Role in Psychiatric Disorders.
    Reyad AA; Mishriky R
    Psychiatr Danub; 2019 Jun; 31(2):157-161. PubMed ID: 31291219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism.
    Citrome L
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):893-903. PubMed ID: 24793403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.
    Schoemaker J; Stet L; Vrijland P; Naber D; Panagides J; Emsley R
    Pharmacopsychiatry; 2012 Jul; 45(5):196-203. PubMed ID: 22454251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asenapine-Induced Acute Dystonia in an Adolescent Male.
    Bhuyan D; Ghosh S; Bhattacharya A; Praharaj SK
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):955-956. PubMed ID: 27154343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model.
    Ohyama M; Kondo M; Yamauchi M; Imanishi T; Koyama T
    Acta Neuropsychiatr; 2016 Dec; 28(6):327-336. PubMed ID: 27099073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Insight in Improving Therapeutic Efficacy of Antipsychotic Agents: An Overview of Improved In Vitro and In Vivo Performance, Efficacy Upgradation and Future Prospects.
    Ei Thu H; Hussain Z; Shuid AN
    Curr Drug Targets; 2018; 19(8):865-876. PubMed ID: 27894237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects.
    Gerrits M; de Greef R; Peeters P
    Biopharm Drug Dispos; 2010 Jul; 31(5-6):351-7. PubMed ID: 20549835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asenapine prescribing patterns in the treatment of manic in- and outpatients: Results from the MANACOR study.
    Grande I; Hidalgo-Mazzei D; Nieto E; Mur M; Sàez C; Forcada I; Vieta E
    Eur Psychiatry; 2015 Jun; 30(4):528-34. PubMed ID: 25682181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asenapine once daily versus twice daily: impact on patient acceptance in a randomized, open-label, 14-day clinical trial.
    Sun X; Hamer R; McEvoy J
    J Clin Psychiatry; 2015 Jul; 76(7):992-3. PubMed ID: 26231009
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.